About Primrose Bio
Primrose Bio is a Healthcare company based in San Diego (United States) founded in 2023. New molecules are discovered, developed, and manufactured in biotechnology. Primrose Bio has raised $15 million across 2 funding rounds from investors including 1315 Capital, Signet Healthcare Partners and Ligand Pharmaceuticals. Its focus areas include Biopharma Outsourcing, CDMO, Biologics and Vaccines. Its competitors include Fina Biosolutions and VaxForm; 1 of its 2 listed competitors has raised funding.
Company details
Primrose Bio was founded in 2023 and is based in San Diego, United States. Operations in the biotechnology sector center on the discovery, development, and manufacturing of new molecules. Pfenex Expression Technology is utilized for complex protein expression. Services are provided to support advancements in molecular biology, with a focus on efficient production processes in the field.
- Headquarters San Diego, United States
- SectorsHealthcare
- Website primrosebio.com
- Social LinkedIn X
- Total Equity Funding$15M (USD)
in 2 rounds
- Investors1315 Capital
& 4 more
Funding Insights of Primrose Bio
Primrose Bio has successfully raised a total of $15M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15M
- Total Rounds 2
- First Round $15M
(Jun 2024)
- Investors Count 5
All 2 funding rounds of Primrose Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2026 | Series B | – | Signet Healthcare Partners | ||
| Jun 2024 | $15M | Series B | – | 1315 Capital | – |
5 investors in total: 5 institutional.
Investors in Primrose Bio
Primrose Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include 1315 Capital, Signet Healthcare Partners and Ligand Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Expansion and growth capital is provided by 1315 Capital to healthcare companies. | 1315capital.com | Philadelphia, United States | ||
| signethealthcarepartners.com | ||||
| ldvp.com | ||||
| agentcapital.com | ||||
| ligand.com |
Investor details for Primrose Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Primrose Bio
18 people are tracked at Primrose Bio (9 in leadership, 9 in team).
| Name | Role | Group |
|---|---|---|
Helge Zieler | CTO | Leadership |
Louis J. Cantolupo | Vice President, Business Development And Marketing | Leadership |
Drew Burch | Chief Executive Officer | Leadership |
Jeff Allen | Senior Vice President, Process And Analytical Development | Leadership |
Diane Retallack | President & COO | Leadership |
Simon Latimer | Chief Financial Officer | Leadership |
Anant Patkar | Senior Director, Technical And Business Operations | Leadership |
Michele Rubino | Chief Business Officer | Leadership |
Russell Coleman | Director Of Strain Engineering | Leadership |
Marc Ayres | Corporate Controller | Team |
Lindsey Jasch | Associate Scientist- Process Development | Team |
Yinghui Lee | Senior Scientist | Team |
Tu-Trinh Nguyen | Principal Lab Automation Engineer | Team |
Alec Tzianabos | Manager, Business Development | Team |
Robert Lasala | Facilities Manager | Team |
Jarad Yost | Scientist, Process Development | Team |
Laila Halim | Senior Research Associate, Process Development | Team |
Ivan Sabath | Senior Scientist | Team |
Complete people profiles for Primrose Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Primrose Bio
3 dated milestones of Primrose Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Primrose Bio is founded.
- Funding First funding round of $15.0M.
- Funding Latest funding round, Series B,.
Competitors of Primrose Bio
Primrose Bio has 2 listed competitors in our database, 1 of them funded. They include Fina Biosolutions and VaxForm.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| finabio.net | 2006 | Rockville, United States | $3M | Biotechnology company specializing in bioconjugation services mainly for vaccine development | ||
| vaxform.com | 2010 | Lehigh, United States | Vaccine formulation development and consulting services are offered. |
Detailed competitors of Primrose Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Primrose Bio
The website of Primrose Bio (primrosebio.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▼ 7.9% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Primrose Bio (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Primrose Bio
Complete news archive for Primrose Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Primrose Bio
Primrose Bio was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Primrose Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Primrose Bio is a funded company, having raised a total of $15M across 2 funding rounds to date. The company's 1st funding round was a Series B of $15M, raised on Jun 2024.
Primrose Bio was founded in 2023 and is based in San Diego, United States. Operations in the biotechnology sector center on the discovery, development, and manufacturing of new molecules. Pfenex Expression Technology is utilized for complex protein expression. Services are provided to support advancements in molecular biology, with a focus on efficient production processes in the field.
Primrose Bio's top competitors include Fina Biosolutions and VaxForm.
Primrose Bio has 5 investors. Key investors include 1315 Capital, Signet Healthcare Partners, Ligand Pharmaceuticals, LDV Partners, and Agent Capital.